Marcin S, Lene T, Richard JW, Marina B, Peter VB, George AWB, Emilio F, Frederique G, Annamaria I, Peter M, Ingrid M, Esperanza N, Wolfgang ASandMaria, Antonietta D
DIABETIC RETINOPATHY The relationship between DR and GLP-1 RAs remains controversial
Unlike many products on the market, it contains no "natural flavors" (aka additives hiding under a healthy label)
Multiple studies have highlighted the glycemic, weight, and cardiac benefits of semaglutide, a glucagon-like peptide-1 receptor agonist (GLP1-RA), treatment in patients with or without type 2 diabetes (T2D)
GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis
Results Disclaimer